StockNews.com initiated coverage on shares of Aspira Women’s Health (NASDAQ:AWH – Free Report) in a research report sent to investors on Wednesday. The firm issued a hold rating on the stock.
Separately, Alliance Global Partners lowered their price objective on shares of Aspira Women’s Health from $7.00 to $5.50 and set a buy rating for the company in a research note on Wednesday, August 14th.
Check Out Our Latest Stock Analysis on AWH
Aspira Women’s Health Stock Down 1.7 %
Aspira Women’s Health (NASDAQ:AWH – Get Free Report) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. The business had revenue of $2.42 million during the quarter, compared to analyst estimates of $2.60 million. During the same period in the previous year, the business posted ($0.28) earnings per share. Equities research analysts anticipate that Aspira Women’s Health will post -1.26 EPS for the current year.
Institutional Trading of Aspira Women’s Health
An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. grew its stake in shares of Aspira Women’s Health Inc. (NASDAQ:AWH – Free Report) by 88.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 236,396 shares of the company’s stock after purchasing an additional 111,022 shares during the quarter. B. Riley Wealth Advisors Inc. owned 1.90% of Aspira Women’s Health worth $352,000 at the end of the most recent quarter. 12.19% of the stock is owned by hedge funds and other institutional investors.
Aspira Women’s Health Company Profile
Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.
Read More
- Five stocks we like better than Aspira Women’s Health
- ESG Stocks, What Investors Should Know
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- How to Use the MarketBeat Excel Dividend Calculator
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for Aspira Women's Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspira Women's Health and related companies with MarketBeat.com's FREE daily email newsletter.